GlassScriptPhysician profile
Carlos E Menendez
NPI 1346268513
$11,103.28
in general payments reported to CMS, 2019-2025
56 companies · $648 in 2025
The $648 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,159 · 2020: $1,579 · 2021: $1,662 · 2022: $1,908 · 2023: $1,653 · 2024: $1,495 · 2025: $648.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,716 · Gift: $59.40 · Education: $20.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,715.64 |
| Gift | $59.40 |
| Education | $20.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $1,514.34 | 2019-2024 | Afrezza |
| Novo Nordisk INC | $1,507.39 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $952.84 | 2019-2025 | Mounjaro, Jardiance, Lyumjev |
| Abbott Laboratories | $841.64 | 2020-2025 | Freestyle Libre 3 |
| Ibsa Pharma INC. | $662.13 | 2019-2025 | Tirosint, Licart, Flector |
| Sanofi-Aventis U.S. LLC | $654.10 | 2019-2025 | |
| Abbvie INC. | $574.18 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $534.62 | 2022-2025 | |
| Amarin Pharma, INC. | $461.87 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $429.19 | 2019-2022 | |
| Dexcom, INC. | $258.24 | 2019-2025 | Dexcom G6 Transmitter |
| Tandem Diabetes Care, INC. | $247.83 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Cequr Corporation | $222.55 | 2022-2025 | Cequr Simplicity |
| Janssen Research & Development, LLC | $222.00 | 2021 | |
| Insulet Corporation | $204.76 | 2019-2022 |
Show all 52 companies
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Menendez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.